Overall survival and EFS of NOD/SCID engrafting and nonengrafting AML samples. (A) Overall survival data of NOD/SCID engrafting and nonengrafting AML samples. The overall and event-free survival data of 25 de novo intermediate-risk AML cases (< 60 years old) that received intensive multi-agent chemotherapy. Four cases were censored at allograft in first complete remission (2 in each group). NOD/SCID engrafting AML cases had a poor overall survival that was statistically lower than NOD/SCID nonengrafting AML cases. (B) Event-free data of NOD/SCID engrafting and nonengrafting AML samples. The event-free survival data of 25 de novo intermediate-risk AML cases (< 60 years old) that received intensive multi-agent chemotherapy. Four cases were censored at allograft in first complete remission (2 patients in each group). NOD/SCID engrafting AML cases had a poor event-free survival when compared with nonengrafting AML cases, though this did not reach statistical significance.